Ribociclib Recommended for EU Approval in Frontline HR+/HER2- Breast Cancer

June 23, 2017 – The Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency (EMA), recommended approval of ribociclib for use in combination with an aromatase inhibitor as a first-line treatment for postmenopausal women with hormone receptor (HR)-positive /HER2-negative locally advanced or metastatic breast cancer. Ribociclib, in combination with an aromatase inhibitor, was shown to reduce the risk for disease … (leggi tutto)